Bausch Health Companies (NYSE:BHC - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect Bausch Health Companies to post earnings of $1.46 per share and revenue of $2.29 billion for the quarter. Bausch Health Companies has set its FY 2025 guidance at EPS.
Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Bausch Health Companies Stock Performance
Shares of BHC traded down $0.07 during mid-day trading on Monday, reaching $5.38. The company had a trading volume of 482,600 shares, compared to its average volume of 2,699,117. The company's 50 day simple moving average is $6.23 and its 200 day simple moving average is $7.31. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -44.79, a P/E/G ratio of 0.37 and a beta of 0.43. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $9.85.
Analyst Ratings Changes
A number of analysts have weighed in on BHC shares. Royal Bank of Canada decreased their target price on shares of Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a research note on Monday, April 7th. Jefferies Financial Group restated a "hold" rating and set a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Finally, StockNews.com cut Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $7.17.
Check Out Our Latest Stock Analysis on BHC
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Read More
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
